SEC 8-K filings, classified by Claude with reasoning. Ingested in near-real time from EDGAR's filing stream, reconciled overnight.
Material 8-K events ordered by the time EDGAR accepted them. New filings appear at the top automatically — no refresh needed. Only filings ingested in near-real-time appear here; the daily-index reconciliation backstop fills in the catalog overnight, but those rows don't carry a sub-day timestamp and land on the Latest view instead.
This 8-K Item 5.07 discloses the results of MaxCyte's 2026 annual stockholder meeting held on June 17, 2026, including voting outcomes for two proposals: election of three Class II directors (Patrick Balthrop, Cynthia Collins, and Stanley Erck) and ratification of CohnReznick LLP as the independent auditor. The tabulated vote counts for each nominee and proposal are the core disclosure, which is the standard format for shareholder vote results under Item 5.07.
The filing discloses unregistered issuances of Common Stock on three dates (May 12, May 28, and June 15, 2026) totaling approximately 308,679 shares in exchange for redemptions of Series A1 and Series A Preferred Stock. The conversion prices declined sharply from $6.36 to $5.41 to $4.30 per share over the period, indicating deteriorating valuation. These are classic dilutive equity issuances that would materially affect shareholder ownership and are properly classified under Item 3.02.
The filing discloses financial and operational results for the three months and year ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, reporting quarterly and annual financial results for a public company.
Dogwood Therapeutics held its Annual Meeting of Stockholders on June 16, 2026, with shareholders voting on five proposals: election of seven directors, ratification of Forvis Mazars, LLP as auditor, amendment to the Certificate of Incorporation to increase authorized shares, Say-on-Frequency advisory vote, and Say-on-Pay advisory vote. All proposals were approved by the required vote margins.
The filing discloses unregistered sales of Class C common stock on three dates (April 15, May 14, and June 12, 2026) totaling 573,657 shares for approximately $9.6 million in aggregate consideration. Item 3.02 specifically governs unregistered equity issuances, and the company explicitly states the sales were exempt under Section 4(a)(2) and Regulation S. This is a classic dilutive issuance that would materially affect a reasonable investor's assessment of share dilution and capital structure.
The Board elected Jill Livesay as a non-employee director effective July 1, 2026, and appointed her to the Audit Committee, expanding the Board from eight to nine members.
This 8-K discloses the results of Annovis Bio's 2026 Annual Meeting of Stockholders held on June 17, 2026, under Item 5.07. The filing reports voting outcomes for five proposals: election of five directors, ratification of Ernst & Young LLP as independent auditors, amendment to the 2019 Equity Incentive Plan to increase authorized shares, advisory vote on named executive officer compensation, and advisory vote on the frequency of future compensation votes. All proposals were approved. This is a routine but material shareholder vote disclosure required by Item 5.07 of Form 8-K.
This is a clear disclosure of shareholder vote results from Best Buy's June 12, 2026 Annual Meeting of Shareholders under Item 5.07. The filing reports voting outcomes on five matters: election of 13 directors, ratification of Deloitte & Touche LLP as independent auditor, advisory vote on executive compensation, and two shareholder proposals. All directors were elected with substantial majorities, the auditor was ratified, and executive compensation was approved, making this a material governance event that affects investor understanding of the company's board composition and shareholder sentiment.
John E. Gallagher has been appointed as Executive Vice President and Chief Financial Officer of CONMED Corporation, effective July 15, 2026, with a compensation package including a base salary of $650,000 and equity grants totaling approximately $3.8 million.
This is a clear disclosure of shareholder voting results from BayCom Corp's 2026 Annual Meeting of Shareholders held on June 16, 2026. The filing reports final voting tallies for three proposals: election of nine directors, advisory vote on executive compensation, and ratification of Baker Tilly US, LLP as independent auditor. All three proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure under Item 5.07.
Cory T. Newsom was appointed as Chief Executive Officer effective upon the retirement of Curtis C. Griffith on December 31, 2026. Newsom, an internal candidate with deep institutional knowledge as President since 2019 and board member since 2008, will assume leadership while Griffith remains as Chairman.
South Plains Financial terminated a Board Representation Agreement with Henry TAW LP, a shareholder that originally owned approximately 16% and now owns less than 10% of outstanding shares. The termination reflects the Company's maturation as a public entity and shift toward a broader shareholder base.
South Plains Financial entered into a stock repurchase agreement with retiring CEO Curtis C. Griffith to repurchase 300,000 shares at fair market value, approved by the board with Griffith recused. The repurchase is a related-party transaction tied to his retirement.
The filing discloses Odyssey Therapeutics' financial results for the three months ended March 31, 2026, with a press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement under Item 2.02, which is the designated Item for disclosure of results of operations and financial condition.
DUOS Technologies entered into an underwritten registered direct offering of 2,000,000 shares of common stock and 3,800,000 pre-funded warrants (exercisable at $0.001) for approximately $55 million in gross proceeds. The combination of a substantial equity issuance and highly dilutive pre-funded warrants represents a material capital raise that will significantly dilute existing shareholders.
QVC Inc. and its affiliates filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of Texas on April 16, 2026. Although this Item 7.01 disclosure focuses on the filing of monthly operating reports required by the Bankruptcy Code, it explicitly references and incorporates the prior 8-K filing disclosing the Chapter 11 Cases themselves. The bankruptcy filing is the material event that triggered this disclosure and is terminal in nature, representing the most significant financial distress signal.
Fiserv entered into an Underwriting Agreement on June 16, 2026, to issue €1 billion in senior notes (€500M due 2030 at 3.750% and €500M due 2034 at 4.250%) in a public offering expected to close June 23, 2026. While this is a debt issuance rather than a traditional M&A transaction, Item 1.01 ("Entry into a Material Definitive Agreement") captures material financing arrangements. The €1 billion aggregate principal amount and the formal underwriting structure with major investment banks (Citigroup, J.P. Morgan, TD, Wells Fargo) indicate materiality to investors assessing the company's capital structure and liquidity.
Plains GP Holdings terminated two material credit facilities (the Existing Revolving Credit Agreement and the Hedged Inventory Facility) and closed a new Revolving Credit Agreement, representing a routine refinancing of its credit arrangements.
The filing discloses that QVC Group, Inc. and certain affiliates filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas on April 16, 2026. While this 8-K is technically filed under Item 7.01 (Regulation FD Disclosure) to furnish monthly operating reports required by the Bankruptcy Code, the core material event is the Chapter 11 bankruptcy filing itself, which was previously disclosed on April 16, 2026. This is a terminal signal event of the highest materiality.
The filing discloses the appointment of Michael Feigin to CitroTech's board of directors on June 17, 2026, effective immediately, to fill one of two vacancies created by director resignations. While the section also reports the resignations of Theodore Ralston and Jeffery Pomerantz, the principal action disclosed is the appointment of a new director with detailed biographical information and committee assignments, making exec_appointment the most salient event. Board composition changes are material to investors assessing governance and oversight.
HEICO entered into a fourth amendment to its revolving credit facility on June 11, 2026, which increased capacity from $2.0 billion to $2.2 billion, extended maturity to June 11, 2031, and modified rating-based pricing terms. While this is a material refinancing and credit facility modification that affects the company's financial flexibility and debt structure, it is not a traditional M&A transaction. However, Item 1.01 is being used here, which typically covers material definitive agreements including significant credit facility amendments. The materiality is clear given the $200 million capacity increase and five-year maturity extension, but the event is more accurately characterized as a material credit facility amendment rather than M&A activity proper.
This Item 5.07 disclosure reports the final voting results from Sabra Health Care REIT's annual meeting of stockholders held on June 17, 2026. The filing presents detailed voting tallies for three matters: election of seven directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and advisory approval of named executive officer compensation. Shareholder vote results are material to investors as they confirm governance composition and audit oversight for the fiscal year.
Plains All American Pipeline entered into a new $2.7 billion senior unsecured revolving credit facility on June 12, 2026, which replaces two prior credit agreements and expands to $4.0 billion. This consolidation of two existing facilities into a single, larger credit arrangement represents a material refinancing that enhances the Partnership's capital structure and financial flexibility.
Virco held its 2026 Annual Meeting of Shareholders on June 16, 2026, with voting results on three matters: election of directors Craig L. Levra and Robert R. Lind, advisory approval of named executive officer compensation, and ratification of Baker Tilly US, LLP as independent auditor. All three proposals passed with substantial majorities.
Daniel L. Poland, Executive Vice President and Chief Enterprise Transformation Officer, is stepping down from his current role effective August 3, 2026, with a transition period extending to January 10, 2027. This is a clear executive departure of a named officer at the C-suite level, making it material to investors assessing the company's leadership and operational continuity.
The company issued a press release on June 17, 2026 reaffirming full-year 2026 revenue growth guidance previously provided in the first quarter earnings release, disclosed under Item 2.02 with the press release furnished as Exhibit 99.1.
Jayant Chauhan was appointed as Executive Vice President and Chief Financial Officer, effective July 6, 2026, replacing interim CFO Marissa Espineli. The appointment includes a base salary of $460,000, bonus targets, an RSU grant of $1.3 million, and severance provisions.
The Company entered into a Third Amended and Restated Operating Agreement on June 15, 2026, which amended the operating agreement to reflect the liquidation and dissolution of Series I and updated indemnification provisions. This represents a material structural change to the Company's organizational documents and governance framework.
The Company resubmitted a New Drug Application (NDA) to the FDA for relacorilant, a treatment for Cushing's syndrome. This is a material regulatory milestone for a biopharmaceutical company, as NDA resubmission represents progress toward potential commercialization of a key product candidate. However, it does not fit neatly into the more specific event categories (e.g., it is not an earnings release, M&A activity, or executive change), making "other_material" the most appropriate classification.
DLH Holdings entered into a Second Amendment to its secured credit agreement on June 11, 2026, modifying key financial covenants including increased leverage ratio thresholds (5.0x to 5.5x) and reduced fixed charge coverage minimums, along with modifications to EBITDA and debt definitions. The covenant relief and add-backs for restructuring charges and lease termination costs indicate the company sought to avoid or address covenant breach, signaling financial stress and potential liquidity challenges.
The filing discloses results of T1 Energy Inc.'s annual meeting of stockholders held on June 17, 2026, under Item 5.07. Four proposals were submitted to a vote: election of eight directors, ratification of KPMG LLP as independent auditor, advisory vote on named executive officer compensation, and approval of an amendment to increase authorized common shares from 500 million to 1 billion. All proposals passed with substantial majorities. This is a material disclosure of shareholder voting outcomes that affects investor understanding of corporate governance and capital structure.
This is a clear disclosure of shareholder vote results from Century Aluminum's 2026 Annual Meeting held on June 15, 2026. The filing reports voting outcomes for three proposals: election of seven directors, ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on named executive officer compensation. All three proposals passed with substantial majorities, and the detailed vote tallies (for, against, withheld, abstain, broker non-votes) are characteristic of Item 5.07 shareholder vote disclosures.
Allurion Technologies implemented a 1-for-15 reverse stock split, approved by stockholders at the December 2025 Annual Meeting, with the Charter Amendment filed on June 12, 2026 and effective June 17-18, 2026. This material corporate action affects the company's share structure, trading symbol, and terms of warrants and convertible securities.
Stacey Moser was appointed as Chief Customer Officer, with the appointment announced on June 17, 2026 as part of organizational changes. The appointment is accompanied by a comprehensive compensation package including $500,000 in RSU equity awards and $500,000 in cash retention awards with specific vesting schedules and severance acceleration provisions.
This Item 5.07 filing discloses the complete results of GeoVax Labs' annual stockholder meeting held on June 17, 2026, including voting outcomes on director elections, warrant exercise proposals, auditor ratification, and executive compensation advisory votes. The disclosure of shareholder voting results on material matters such as director elections and dilutive warrant issuances (totaling over 3.8 million shares) is material to investors assessing corporate governance and capital structure changes.
This Item 5.07 filing discloses the results of the Annual Meeting of Stockholders held on June 16, 2026, including voting outcomes for three proposals: election of two Class II directors (Robert Gheewalla and Michael Koester), ratification of Deloitte & Touche LLP as independent auditor, and approval of a charter amendment regarding liquidation voting thresholds. The filing presents certified vote tabulations for each proposal, which is the core disclosure required under Item 5.07.
This is a classic Item 5.07 disclosure of shareholder vote results from Liquidia's June 16, 2026 annual meeting. The filing reports voting outcomes on three proposals: election of three Class II directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and non-binding advisory approval of NEO compensation. All three proposals passed with substantial majorities, and the detailed vote tallies (For/Against/Abstain/Broker Non-Votes) are provided for each matter.
Medalist Diversified entered into a definitive agreement to sell Brookfield Center, a commercial real property, for $10.25 million. This disposition of a material asset is substantial relative to the registrant's size and will materially affect its asset base and financial position.
At the Annual Meeting of stockholders, four proposals were voted on and all passed with substantial majorities: election of two Class III directors (Kavanaugh and Farmer), advisory approval of named executive officer compensation, ratification of Cherry Bekaert LLP as independent auditor, and approval of a charter amendment to protect net operating loss and net capital loss carryforwards through transfer restrictions.
Flag Ship Acquisition Corp held an Extraordinary General Meeting on June 11, 2026, where shareholders voted to extend the business combination deadline from June 20, 2026 to June 20, 2027, with the Extension Proposal receiving 2,993,175 votes in favor and 1,267,577 against, achieving the required two-thirds majority. The vote resulted in 1,507,257 ordinary shares being redeemed by shareholders exercising redemption rights, materially affecting the company's capital structure and Trust Account balance.
Flag Ship Acquisition Corp amended its Amended and Restated Memorandum and Articles of Association and its Investment Management Trust Agreement to extend the deadline for consummating a business combination from June 20, 2026 to June 20, 2027, with up to twelve one-month extensions contingent on sponsor funding. These governance amendments materially affect the SPAC's timeline and sponsor obligations but do not constitute a discrete M&A transaction.
The filing references a "Common Shares Purchase Agreement dated June 16, 2026" as Exhibit 10.1, which is the hallmark disclosure of a dilutive equity issuance. Although the Item 3.02 section itself is not provided in full, the exhibit and the boilerplate language disclaiming any offer to sell shares are consistent with a private placement or PIPE transaction. The presence of an executed purchase agreement for common shares indicates a material equity issuance that would dilute existing shareholders.
Eva Live Inc. announced the formation of its first wholly owned subsidiary, Eva Defense Inc., described as a "strategic initiative designed to pursue acquisitions and partnerships within the rapidly growing drone, autonomous systems, and defense technology sectors." While this is a corporate restructuring event involving the creation of a subsidiary for M&A purposes, it does not constitute a completed acquisition, disposition, merger, or change of control (which would trigger ma_activity). The disclosure is material as it signals a strategic pivot and capital allocation toward a new business segment, but the event itself—subsidiary formation—does not fit cleanly into the more specific event categories.
John E. Gallagher III, Senior Vice President and Chief Financial Officer, resigned effective July 14, 2026. Faiz Mohammed was appointed as Interim CFO to manage the transition.
Collective Acquisition Corp. II completed unregistered sales of equity securities, including exercise of an over-allotment option generating $33 million in additional proceeds and a related private placement of $330 thousand, as part of the SPAC's IPO capitalization.
Ascent Solar held its 2026 Annual Meeting of Stockholders on June 17, 2026, with stockholders voting on five proposals: election of two Class A directors (Louis Berezovsky and Forrest Reynolds), ratification of Haynie & Company as independent auditor, approval of an amendment to the 2023 Equity Incentive Plan increasing the share reserve from 893,611 to 1,700,000 shares, advisory approval of named executive officer compensation, and approval to adjourn the meeting. All proposals were approved or elected as indicated.
This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on June 16, 2026. The filing presents voting outcomes for three proposals: election of five directors, ratification of BDO USA as independent auditors, and advisory approval of executive compensation. These are routine but material governance matters that affect investor understanding of board composition and corporate oversight.
The Company amended pre-funded warrants originally issued in October 2025 to remove exercisability restrictions, enabling R01 Fund LP and Framework Ventures IV L.P. to exercise their warrants on a cashless basis, resulting in the issuance of an aggregate of 22,614,600 shares of Common Stock and increasing outstanding shares from approximately 27.8 million to 50.4 million shares.
This is a clear disclosure of shareholder vote results from Vuzix's June 16, 2026 annual meeting of stockholders. The filing reports voting outcomes on three matters: (i) election of five directors (Paul Travers, Grant Russell, Timothy Harned, Paula Whitten-Doolin, and Alasdair MacKinnon), (ii) ratification of Withum Smith+Brown, PC as independent auditor, and (iii) advisory approval of named executive officer compensation. The detailed vote tallies (votes for, against, abstained, and broker non-votes) are presented in tabular form, which is the standard format for Item 5.07 shareholder vote results disclosures.
This is a clear disclosure of shareholder vote results from the June 17, 2026 annual meeting of stockholders, covering four proposals: election of six directors, advisory vote on named executive officer compensation, approval of an amendment to the 2019 Stock Incentive Plan, and ratification of the independent auditor (BDO USA, P.C.). The filing presents detailed voting tallies for each proposal, which is the hallmark of Item 5.07 disclosure and the shareholder_vote_results event type.